Taken together, these results indicate that microRNA-29c acting on FOS may play an important role in NASH through the IL-17 signaling pathway in NASH patients, ultimately leading to an imbalance in TH17/Tregs inflammatory cell ratio. Here, IL17A is linked to metabolic dysfunction-associated steatohepatitis.